|  |
September 2003 Stock Report
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| GENOME THERAPEUTICS CORP |
$3.03 |
76% |
115% |
$79 |
$32 |
$47 |
$15 |
152 |
$0.3 |
-$34.8 |
0.9 |
2.8 |
| HUMAN GENOME SCIENCES |
$13.17 |
74% |
14% |
$1,701 |
$1,158 |
$543 |
$503 |
1086 |
$0.5 |
-$165.3 |
7.0 |
1.0 |
| INCYTE CORP |
$4.54 |
70% |
18% |
$328 |
$320 |
$7 |
$172 |
585 |
$0.0 |
-$223.1 |
1.4 |
0.5 |
| MILLENNIUM PHARMACEUTICALS |
$14.77 |
80% |
56% |
$4,412 |
$1,514 |
$2,898 |
$83 |
2079 |
$1.4 |
-$551.4 |
2.7 |
1.0 |
| MYRIAD GENETICS |
$11.36 |
52% |
-25% |
$308 |
$88 |
$220 |
$0 |
491 |
$0.4 |
-$22.1 |
4.0 |
1.2 |
| 1st Generation Genomics Average |
|
70% |
36% |
$1,365 |
$622 |
$743 |
$155 |
|
$0.5 |
-$199.4 |
3.2 |
1.3 |
| 1st Generation Genomics Median |
|
74% |
18% |
$328 |
$320 |
$220 |
$83 |
|
$0.4 |
-$165.3 |
2.7 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ACLARA BIOSCIENCES |
$3.94 |
88% |
146% |
$141 |
$78 |
$63 |
$0 |
95 |
$0.7 |
-$24.9 |
3.1 |
0.5 |
| AFFYMETRIX |
$22.04 |
74% |
10% |
$1,299 |
$416 |
$883 |
$369 |
877 |
$1.0 |
-$50.9 |
8.2 |
3.6 |
| CALIPER TECHNOLOGIES |
$6.06 |
90% |
43% |
$171 |
$134 |
$37 |
$1 |
251 |
$0.1 |
-$39.9 |
3.4 |
0.7 |
| CEPHEID |
$4.61 |
70% |
12% |
$150 |
$11 |
$139 |
$0 |
148 |
$0.9 |
-$18.8 |
0.6 |
1.7 |
| CIPHERGEN BIOSYSTEMS |
$11.85 |
86% |
309% |
$341 |
$27 |
$314 |
$30 |
323 |
$1.0 |
-$36.8 |
0.7 |
2.0 |
| COMBIMATRIX |
$4.45 |
88% |
na |
$115 |
na |
na |
$0 |
14 |
na |
-$26.7 |
na |
na |
| COMPUGEN |
$5.25 |
83% |
369% |
$138 |
na |
na |
$0 |
176 |
na |
na |
na |
na |
| ILLUMINA |
$5.15 |
86% |
52% |
$168 |
$51 |
$117 |
$25 |
233 |
$0.5 |
-$35.8 |
1.4 |
2.6 |
| NANOGEN |
$3.50 |
70% |
101% |
$78 |
$26 |
$51 |
$0 |
195 |
$0.3 |
-$42.7 |
0.6 |
0.4 |
| ORCHID BIOSCIENCES |
$1.24 |
62% |
82% |
$79 |
na |
na |
$2 |
492 |
na |
-$17.1 |
na |
0.2 |
| SEQUENOM |
$3.42 |
82% |
84% |
$136 |
$76 |
$61 |
$10 |
216 |
$0.3 |
-$34.2 |
2.2 |
0.3 |
| TRANSGENOMIC |
$1.64 |
39% |
-60% |
$39 |
$3 |
$36 |
$1 |
326 |
$0.1 |
-$14.4 |
0.2 |
0.3 |
| Genomic Supply Average |
|
76% |
104% |
$238 |
$91 |
$189 |
$37 |
|
$0.5 |
-$31.1 |
2.3 |
1.2 |
| Genomic Supply Median |
|
82% |
82% |
$139 |
$51 |
$63 |
$1 |
|
$0.5 |
-$34.2 |
1.4 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| APPLIED MOLECULAR EVOLUTION |
$9.73 |
87% |
154% |
$203 |
$58 |
$144 |
$10 |
106 |
$1.4 |
-$13.1 |
4.4 |
1.3 |
| ARENA PHARMACEUTICALS |
$7.25 |
87% |
29% |
$207 |
$174 |
$33 |
$0 |
336 |
$0.1 |
-$35.2 |
4.9 |
0.7 |
| CELERA GENOMICS GROUP |
$11.04 |
77% |
50% |
$795 |
na |
na |
$0 |
na |
na |
na |
na |
na |
| CURAGEN CORP |
$5.00 |
71% |
28% |
$248 |
$395 |
-$147 |
$150 |
857 |
-$0.2 |
-$64.6 |
6.1 |
0.5 |
| DECODE GENETICS |
$4.25 |
79% |
100% |
$228 |
$79 |
$148 |
$46 |
530 |
$0.3 |
-$52.2 |
1.5 |
0.5 |
| EXELIXIS |
$7.00 |
72% |
76% |
$498 |
$204 |
$294 |
$60 |
550 |
$0.5 |
-$92.2 |
2.2 |
1.1 |
| GENAISSANCE PHARMACEUTICALS |
$1.88 |
83% |
309% |
$43 |
$30 |
$13 |
$0 |
104 |
$0.1 |
-$18.9 |
1.6 |
0.2 |
| GENE LOGIC |
$4.90 |
57% |
-36% |
$152 |
$157 |
-$5 |
$1 |
264 |
$0.0 |
-$23.2 |
6.8 |
0.4 |
| GENENCOR INTERNATIONAL |
$16.24 |
93% |
66% |
$958 |
$139 |
$819 |
$57 |
1098 |
$0.7 |
na |
na |
1.8 |
| LARGE SCALE BIOLOGY |
$1.24 |
67% |
-26% |
$32 |
$19 |
$13 |
$0 |
114 |
$0.1 |
-$30.5 |
0.6 |
0.2 |
| LEXICON GENETICS |
$5.25 |
70% |
29% |
$328 |
$108 |
$221 |
$4 |
579 |
$0.4 |
-$68.6 |
1.6 |
1.0 |
| LYNX THERAPEUTICS |
$5.83 |
69% |
39% |
$27 |
$7 |
$20 |
$1 |
128 |
$0.2 |
-$15.9 |
0.5 |
0.2 |
| MAXYGEN |
$10.59 |
68% |
67% |
$369 |
$198 |
$171 |
$0 |
280 |
$0.6 |
-$15.7 |
12.6 |
0.9 |
| NUVELO |
$2.90 |
72% |
93% |
$185 |
$41 |
$144 |
$5 |
98 |
$1.5 |
-$54.3 |
0.8 |
0.9 |
| PARADIGM GENETICS |
$1.33 |
69% |
161% |
$43 |
$11 |
$32 |
$2 |
194 |
$0.2 |
-$16.5 |
0.7 |
0.4 |
| RIGEL PHARMACEUTICALS |
$13.15 |
72% |
-5% |
$194 |
$22 |
$172 |
$0 |
160 |
$1.1 |
-$31.2 |
0.7 |
1.4 |
| SANGAMO BIOSCIENCES |
$3.59 |
65% |
92% |
$89 |
$49 |
$40 |
$0 |
74 |
$0.5 |
-$11.6 |
4.2 |
0.7 |
| ZYMOGENETICS |
$15.07 |
84% |
90% |
$697 |
$268 |
$429 |
$0 |
364 |
$1.2 |
-$52.5 |
5.1 |
1.6 |
| Genomic Targets Average |
|
74% |
73% |
$294 |
$115 |
$149 |
$19 |
|
$0.5 |
-$37.3 |
3.4 |
0.8 |
| Genomic Targets Median |
|
72% |
67% |
$205 |
$79 |
$144 |
$1 |
|
$0.4 |
-$30.9 |
1.9 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| EDEN BIOSCIENCES |
$1.31 |
58% |
-29% |
$32 |
$26 |
$6 |
$0 |
55 |
$0.1 |
-$11.6 |
2.3 |
0.2 |
| EMBREX |
$9.90 |
73% |
-11% |
$81 |
$7 |
$74 |
$0 |
241 |
$0.3 |
na |
na |
1.3 |
| IDEXX LABORATORIES |
$43.04 |
94% |
41% |
$1,480 |
$175 |
$1,304 |
$0 |
1281 |
$1.0 |
na |
na |
4.2 |
| IMMUCELL CORP |
$2.75 |
57% |
54% |
$8 |
$4 |
$3 |
$0 |
26 |
$0.1 |
na |
na |
0.8 |
| NEOGEN |
$19.07 |
98% |
44% |
$119 |
$8 |
$110 |
$0 |
265 |
$0.4 |
na |
na |
4.8 |
| Agbio/enviro. Average |
|
76% |
20% |
$344 |
$44 |
$299 |
$0 |
|
$0.4 |
na |
na |
2.3 |
| Agbio/enviro. Median |
|
73% |
41% |
$81 |
$8 |
$74 |
$0 |
|
$0.3 |
na |
na |
1.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALEXION PHARMACEUTICALS |
$16.51 |
82% |
41% |
$301 |
$253 |
$47 |
$124 |
172 |
$0.3 |
-$85.9 |
2.9 |
0.8 |
| ATHEROGENICS |
$16.49 |
88% |
164% |
$602 |
$73 |
$529 |
$100 |
85 |
$6.2 |
-$46.0 |
1.6 |
3.5 |
| AUTOIMMUNE |
$1.39 |
62% |
65% |
$24 |
$11 |
$12 |
$0 |
2 |
$6.2 |
na |
na |
0.2 |
| CONNETICS CORP |
$15.71 |
83% |
82% |
$498 |
$29 |
$469 |
$80 |
190 |
$2.5 |
-$21.5 |
1.3 |
2.9 |
| CORTECH |
$2.80 |
85% |
2% |
$10 |
$0 |
$10 |
$0 |
na |
na |
-$0.5 |
0.0 |
101.4 |
| CYPRESS BIOSCIENCE |
$8.35 |
95% |
620% |
$157 |
$10 |
$146 |
$0 |
10 |
$14.6 |
-$7.0 |
1.5 |
1.3 |
| ICOS CORP |
$37.62 |
82% |
79% |
$2,354 |
$156 |
$2,198 |
$250 |
525 |
$4.2 |
-$162.0 |
1.0 |
3.0 |
| INKINE PHARMACEUTICAL CO |
$3.87 |
77% |
269% |
$181 |
$11 |
$170 |
$12 |
49 |
$3.5 |
-$3.7 |
2.9 |
2.8 |
| LA JOLLA PHARMACEUTICAL CO |
$4.25 |
48% |
-4% |
$181 |
$39 |
$143 |
$1 |
156 |
$0.9 |
-$54.2 |
0.7 |
0.9 |
| PROTEIN DESIGN LABS |
$13.98 |
68% |
67% |
$1,309 |
$592 |
$717 |
$400 |
397 |
$1.8 |
na |
na |
2.1 |
| TANOX |
$20.08 |
88% |
91% |
$891 |
$207 |
$683 |
$5 |
127 |
$5.4 |
-$25.4 |
8.2 |
2.9 |
| Autoimmune Average |
|
78% |
134% |
$592 |
$126 |
$466 |
$88 |
|
$4.6 |
-$45.1 |
2.2 |
11.1 |
| Autoimmune Median |
|
82% |
79% |
$301 |
$39 |
$170 |
$12 |
|
$3.8 |
-$25.4 |
1.5 |
2.8 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALLOS THERAPEUTICS |
$2.95 |
30% |
-65% |
$76 |
$49 |
$27 |
$0 |
92 |
$0.3 |
-$28.4 |
1.7 |
0.4 |
| ANTIGENICS |
$12.34 |
77% |
57% |
$487 |
$103 |
$384 |
$0 |
212 |
$1.8 |
-$54.0 |
1.9 |
1.4 |
| APHTON CORP |
$5.46 |
55% |
109% |
$135 |
$6 |
$129 |
$3 |
56 |
$2.3 |
-$19.7 |
0.3 |
1.0 |
| ARIAD PHARMACEUTICALS |
$6.10 |
82% |
88% |
$238 |
$21 |
$216 |
$6 |
52 |
$4.2 |
-$21.2 |
1.0 |
1.5 |
| AVI BIOPHARMA |
$5.21 |
70% |
-2% |
$162 |
$12 |
$151 |
$0 |
89 |
$1.7 |
-$13.7 |
0.9 |
1.2 |
| BIOMIRA |
$1.93 |
39% |
112% |
$123 |
$83 |
$40 |
$0 |
115 |
$0.3 |
-$17.6 |
4.7 |
1.4 |
| BOSTON LIFE SCIENCES |
$1.67 |
56% |
61% |
$54 |
$0 |
$54 |
$0 |
14 |
$3.9 |
na |
na |
na |
| BRITISH BIOTECH PLC |
$2.55 |
71% |
6% |
$43 |
$284 |
-$241 |
$5 |
96 |
-$2.5 |
-$59.4 |
4.8 |
0.1 |
| CELGENE CORP |
$42.50 |
87% |
161% |
$3,443 |
$257 |
$3,186 |
$400 |
560 |
$5.7 |
na |
na |
5.8 |
| CELL THERAPEUTICS |
$11.31 |
72% |
154% |
$377 |
$110 |
$267 |
$190 |
286 |
$0.9 |
-$121.9 |
0.9 |
1.0 |
| CORIXA CORP |
$8.26 |
84% |
37% |
$453 |
$61 |
$392 |
$106 |
366 |
$1.1 |
-$74.8 |
0.8 |
0.4 |
| CYTOGEN CORP |
$12.61 |
85% |
168% |
$139 |
$11 |
$128 |
$0 |
49 |
$2.6 |
-$7.8 |
1.4 |
0.4 |
| DENDREON |
$8.95 |
85% |
129% |
$394 |
$47 |
$346 |
$0 |
117 |
$3.0 |
-$30.8 |
1.5 |
2.4 |
| DUSA PHARMACEUTICALS |
$5.48 |
80% |
278% |
$77 |
$48 |
$28 |
$1 |
43 |
$0.7 |
-$14.3 |
3.4 |
0.8 |
| ENTREMED |
$4.44 |
68% |
206% |
$141 |
$7 |
$134 |
$0 |
58 |
$2.3 |
-$14.8 |
0.4 |
0.6 |
| EXEGENICS |
$0.60 |
67% |
-3% |
$10 |
$15 |
-$6 |
$0 |
8 |
-$0.7 |
-$3.9 |
3.9 |
0.1 |
| GENAERA |
$4.75 |
88% |
733% |
$172 |
$8 |
$164 |
$0 |
22 |
$7.5 |
-$6.3 |
1.2 |
0.9 |
| GENTA |
$12.53 |
71% |
85% |
$939 |
$103 |
$836 |
$28 |
96 |
$8.7 |
-$38.4 |
2.7 |
2.9 |
| GERON CORP |
$12.98 |
81% |
214% |
$430 |
$40 |
$391 |
$16 |
92 |
$4.2 |
-$31.7 |
1.2 |
1.7 |
| ILEX ONCOLOGY |
$16.07 |
74% |
235% |
$616 |
$161 |
$455 |
$37 |
277 |
$1.6 |
-$99.7 |
1.6 |
1.3 |
| IMCLONE SYSTEMS |
$37.73 |
77% |
375% |
$2,814 |
$293 |
$2,521 |
$242 |
399 |
$6.3 |
-$168.0 |
1.7 |
8.1 |
| IMMUNOGEN |
$4.70 |
78% |
70% |
$191 |
$515 |
-$325 |
$0 |
1618 |
-$0.2 |
na |
na |
0.1 |
| IMMUNOMEDICS |
$7.27 |
75% |
21% |
$363 |
$28 |
$334 |
$0 |
94 |
$3.6 |
na |
na |
2.3 |
| MAXIM PHARMACEUTICALS |
$6.71 |
90% |
215% |
$157 |
$89 |
$68 |
$1 |
115 |
$0.6 |
-$43.9 |
2.0 |
0.4 |
| MEDAREX |
$5.74 |
75% |
63% |
$445 |
$321 |
$123 |
$175 |
431 |
$0.3 |
-$118.5 |
2.7 |
0.7 |
| NAPRO BIOTHERAPEUTICS |
$1.63 |
51% |
46% |
$50 |
$7 |
$44 |
$25 |
151 |
$0.3 |
-$11.0 |
0.6 |
0.5 |
| NEOPHARM |
$15.36 |
82% |
9% |
$289 |
$81 |
$209 |
$0 |
100 |
$2.1 |
-$45.1 |
1.8 |
1.7 |
| NEORX CORP |
$4.96 |
69% |
1317% |
$136 |
$12 |
$123 |
$5 |
36 |
$3.4 |
-$16.5 |
0.7 |
0.6 |
| OSI PHARMACEUTICALS |
$31.72 |
83% |
83% |
$1,148 |
$354 |
$794 |
$295 |
429 |
$1.9 |
-$108.7 |
3.3 |
1.6 |
| OXIGENE |
$11.17 |
58% |
1028% |
$159 |
$10 |
$149 |
$0 |
10 |
$14.9 |
-$5.9 |
1.7 |
1.9 |
| PRAECIS PHARMACEUTICALS |
$6.43 |
89% |
117% |
$334 |
$181 |
$152 |
$33 |
110 |
$1.4 |
-$45.7 |
4.0 |
0.9 |
| PROGENICS PHARMACEUTICALS |
$17.36 |
85% |
232% |
$224 |
$33 |
$191 |
$0 |
100 |
$1.9 |
-$24.4 |
1.4 |
2.4 |
| QLT INC |
$15.83 |
87% |
108% |
$1,088 |
$126 |
$962 |
$172 |
336 |
$2.9 |
na |
na |
2.8 |
| SCICLONE PHARMACEUTICALS |
$7.23 |
74% |
163% |
$277 |
$18 |
$259 |
$6 |
97 |
$2.7 |
-$11.4 |
1.5 |
1.7 |
| SEATTLE GENETICS |
$5.90 |
84% |
95% |
$182 |
$22 |
$160 |
$0 |
97 |
$1.7 |
-$23.8 |
0.9 |
1.7 |
| SPECTRUM PHARMACEUTICALS |
$8.02 |
77% |
702% |
$33 |
na |
na |
$0 |
18 |
na |
-$6.8 |
na |
0.2 |
| SUPERGEN |
$7.40 |
86% |
311% |
$261 |
$32 |
$229 |
$8 |
107 |
$2.1 |
-$46.7 |
0.7 |
0.9 |
| XENOVA GROUP PLC |
$2.10 |
29% |
-60% |
$36 |
$29 |
$7 |
$0 |
134 |
$0.1 |
-$13.9 |
2.1 |
1.3 |
| Cancer Average |
|
73% |
202% |
$439 |
$97 |
$354 |
$46 |
|
$2.6 |
-$40.9 |
1.9 |
1.5 |
| Cancer Median |
|
77% |
111% |
$208 |
$47 |
$160 |
$1 |
|
$1.9 |
-$24.4 |
1.6 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| CV THERAPEUTICS |
$21.89 |
53% |
5% |
$622 |
$401 |
$221 |
$196 |
205 |
$1.1 |
-$82.9 |
4.8 |
1.1 |
| ENCYSIVE PHARMACEUTICALS |
$5.95 |
89% |
118% |
$264 |
$48 |
$217 |
$0 |
104 |
$2.1 |
-$18.6 |
2.6 |
1.2 |
| MEDICINES COMPANY |
$24.01 |
76% |
126% |
$1,131 |
$131 |
$1,000 |
$0 |
147 |
$6.8 |
-$25.7 |
5.1 |
2.5 |
| QUESTCOR PHARMACEUTICALS |
$0.90 |
66% |
-11% |
$40 |
$15 |
$25 |
$3 |
52 |
$0.5 |
-$7.1 |
2.1 |
0.4 |
| Cardiovascular Average |
|
71% |
60% |
$514 |
$149 |
$366 |
$50 |
|
$2.6 |
-$33.6 |
3.7 |
1.3 |
| Cardiovascular Median |
|
71% |
62% |
$443 |
$89 |
$219 |
$2 |
|
$1.6 |
-$22.1 |
3.7 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALBANY MOLECULAR RESEARCH |
$14.25 |
78% |
-16% |
$453 |
$124 |
$329 |
$66 |
860 |
$0.4 |
na |
na |
2.5 |
| ARGONAUT TECHNOLOGIES |
$1.35 |
77% |
125% |
$27 |
$23 |
$4 |
$12 |
215 |
$0.0 |
-$10.1 |
2.3 |
0.2 |
| ARQULE |
$4.20 |
65% |
-16% |
$98 |
$83 |
$16 |
$5 |
298 |
$0.1 |
-$3.0 |
27.6 |
0.4 |
| ARRAY BIOPHARMA |
$5.63 |
61% |
-22% |
$159 |
$41 |
$118 |
$0 |
245 |
$0.5 |
-$24.5 |
1.7 |
1.3 |
| BIOCRYST PHARMACEUTICALS |
$6.38 |
87% |
445% |
$113 |
$23 |
$90 |
$0 |
44 |
$2.0 |
-$11.2 |
2.0 |
0.9 |
| DISCOVERY PARTNERS |
$5.68 |
88% |
95% |
$140 |
$71 |
$69 |
$0 |
236 |
$0.3 |
na |
na |
0.7 |
| KOSAN BIOSCIENCES |
$7.65 |
85% |
20% |
$195 |
$53 |
$142 |
$0 |
112 |
$1.3 |
-$10.3 |
5.1 |
1.4 |
| PHARMACOPEIA |
$12.47 |
77% |
55% |
$297 |
$146 |
$150 |
$0 |
687 |
$0.2 |
-$21.8 |
6.7 |
1.0 |
| SYMYX TECHNOLOGIES |
$21.45 |
84% |
102% |
$672 |
$127 |
$545 |
$0 |
213 |
$2.6 |
na |
na |
4.3 |
| VERTEX PHARMACEUTICALS |
$12.18 |
56% |
-34% |
$938 |
$680 |
$258 |
$315 |
980 |
$0.3 |
na |
na |
1.2 |
| Chemistry Average |
|
76% |
75% |
$309 |
$137 |
$172 |
$40 |
|
$0.8 |
-$13.5 |
7.6 |
1.4 |
| Chemistry Median |
|
78% |
38% |
$177 |
$77 |
$130 |
$0 |
|
$0.3 |
-$10.7 |
3.7 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ADOLOR |
$18.17 |
90% |
30% |
$575 |
$137 |
$438 |
$0 |
124 |
$3.5 |
-$45.3 |
3.0 |
2.2 |
| CEPHALON |
$45.76 |
77% |
15% |
$2,542 |
$547 |
$1,995 |
$1,610 |
1271 |
$1.6 |
na |
na |
2.5 |
| DOV PHARMACEUTICALS |
$17.03 |
91% |
296% |
$278 |
$57 |
$221 |
$14 |
32 |
$6.9 |
-$10.4 |
5.5 |
3.4 |
| GUILFORD PHARMACEUTICALS |
$6.03 |
81% |
45% |
$175 |
$66 |
$109 |
$64 |
235 |
$0.5 |
-$44.8 |
1.5 |
0.5 |
| INDEVUS PHARMACEUTICALS |
$5.40 |
78% |
238% |
$254 |
$33 |
$221 |
$72 |
24 |
$9.2 |
-$48.2 |
0.7 |
0.8 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$6.07 |
69% |
118% |
$110 |
$5 |
$106 |
$0 |
11 |
$9.6 |
-$3.0 |
1.5 |
2.5 |
| NEUROCRINE BIOSCIENCES |
$50.05 |
83% |
21% |
$1,575 |
$308 |
$1,267 |
$0 |
276 |
$4.6 |
-$53.6 |
5.8 |
3.7 |
| NYMOX PHARMACEUTICAL |
$2.45 |
54% |
-27% |
$58 |
na |
na |
$0 |
228 |
na |
na |
na |
na |
| PAIN THERAPEUTICS |
$6.03 |
67% |
53% |
$166 |
$46 |
$121 |
$0 |
30 |
$4.0 |
-$18.5 |
2.5 |
1.6 |
| PHARMOS CORP |
$1.95 |
74% |
79% |
$139 |
$17 |
$122 |
$42 |
67 |
$1.8 |
-$18.0 |
0.9 |
1.2 |
| STEMCELLS |
$1.88 |
66% |
144% |
$64 |
$2 |
$62 |
$0 |
28 |
$2.2 |
-$9.6 |
0.2 |
0.4 |
| TITAN PHARMACEUTICALS |
$2.47 |
80% |
68% |
$68 |
$66 |
$2 |
$0 |
72 |
$0.0 |
-$26.1 |
2.5 |
0.3 |
| CNS Average |
|
76% |
90% |
$500 |
$117 |
$424 |
$150 |
|
$4.0 |
-$27.8 |
2.4 |
1.7 |
| CNS Median |
|
78% |
60% |
$170 |
$57 |
$122 |
$0 |
|
$3.5 |
-$22.3 |
2.0 |
1.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| BIOSOURCE INTERNATIONAL |
$7.01 |
88% |
16% |
$64 |
$4 |
$60 |
$0 |
296 |
$0.2 |
na |
na |
1.5 |
| GTC BIOTHERAPEUTICS |
$2.75 |
63% |
141% |
$78 |
$48 |
$30 |
$13 |
182 |
$0.2 |
-$29.6 |
1.6 |
0.4 |
| HARVARD BIOSCIENCE |
$7.50 |
88% |
142% |
$226 |
$9 |
$216 |
$0 |
386 |
$0.6 |
na |
na |
1.3 |
| ICON PLC |
$33.21 |
88% |
53% |
$393 |
na |
na |
$0 |
1637 |
na |
na |
na |
na |
| INVITROGEN CORP |
$56.17 |
89% |
67% |
$2,823 |
$764 |
$2,059 |
$697 |
2744 |
$0.8 |
na |
na |
1.5 |
| MOLECULAR DEVICES CORP |
$17.81 |
86% |
40% |
$266 |
$55 |
$211 |
$0 |
433 |
$0.5 |
na |
na |
1.4 |
| NEOSE TECHNOLOGIES |
$10.04 |
72% |
34% |
$173 |
$52 |
$122 |
$8 |
124 |
$1.0 |
-$33.7 |
1.5 |
0.9 |
| PARAXEL INTERNATIONAL |
$15.65 |
88% |
78% |
$405 |
$76 |
$329 |
$1 |
4930 |
$0.1 |
na |
na |
2.3 |
| PHARMACEUTICAL PRODUCT DEVELOP |
$24.96 |
77% |
26% |
$1,396 |
$186 |
$1,210 |
$6 |
5300 |
$0.2 |
na |
na |
5.1 |
| QIAGEN NV |
$11.08 |
84% |
131% |
$1,614 |
$30 |
$1,584 |
$0 |
1651 |
$1.0 |
na |
na |
32.5 |
| QUINTILES TRANSNATIONAL CORP |
$14.49 |
99% |
49% |
$1,717 |
$731 |
$986 |
$0 |
15548 |
$0.1 |
na |
na |
1.9 |
| CRO/Service/Supply Average |
|
84% |
71% |
$832 |
$196 |
$681 |
$66 |
|
$0.4 |
-$31.6 |
na |
4.9 |
| CRO/Service/Supply Median |
|
88% |
53% |
$393 |
$53 |
$272 |
$0 |
|
$0.4 |
-$31.6 |
na |
1.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ABGENIX |
$14.03 |
83% |
112% |
$1,234 |
$346 |
$888 |
$200 |
387 |
$2.3 |
-$132.7 |
2.6 |
1.3 |
| AEROGEN |
$0.78 |
61% |
42% |
$16 |
$4 |
$12 |
$0 |
80 |
$0.1 |
-$17.2 |
0.3 |
0.1 |
| ALKERMES |
$12.90 |
88% |
72% |
$1,152 |
$158 |
$994 |
$385 |
520 |
$1.9 |
na |
na |
2.4 |
| ANDRX |
$17.81 |
69% |
-21% |
$1,282 |
$67 |
$1,215 |
$0 |
2100 |
$0.6 |
na |
na |
2.6 |
| ARADIGM CORP |
$1.89 |
54% |
-4% |
$103 |
$36 |
$66 |
$0 |
285 |
$0.2 |
-$31.7 |
1.1 |
0.4 |
| ATRIX LABORATORIES |
$20.47 |
66% |
38% |
$429 |
$96 |
$333 |
$0 |
167 |
$2.0 |
-$11.0 |
8.7 |
1.7 |
| BIODELIVERY SCIENCES |
$3.64 |
73% |
121% |
$25 |
$6 |
$20 |
$0 |
19 |
$1.0 |
-$2.3 |
2.5 |
1.8 |
| CIMA LABS |
$28.29 |
92% |
17% |
$410 |
$72 |
$338 |
$0 |
219 |
$1.5 |
na |
na |
1.7 |
| DEPOMED |
$6.10 |
72% |
128% |
$157 |
$13 |
$144 |
$0 |
51 |
$2.8 |
-$25.2 |
0.5 |
2.3 |
| DOR BIOPHARMA |
$0.86 |
50% |
121% |
$24 |
$3 |
$21 |
$0 |
5 |
$4.1 |
-$9.7 |
0.3 |
0.3 |
| DURECT |
$3.50 |
79% |
18% |
$177 |
$37 |
$140 |
$50 |
6 |
$23.3 |
-$23.6 |
1.6 |
0.9 |
| EMISPHERE TECHNOLOGIES |
$6.85 |
74% |
133% |
$124 |
$53 |
$71 |
$34 |
124 |
$0.6 |
-$39.5 |
1.3 |
0.4 |
| ENZON PHARMACEUTICALS |
$11.50 |
55% |
-39% |
$500 |
$100 |
$400 |
$0 |
127 |
$3.2 |
na |
na |
1.9 |
| FLAMEL TECHNOLOGIES SA |
$33.50 |
77% |
1123% |
$547 |
$13 |
$534 |
$2 |
150 |
$3.6 |
-$8.9 |
1.5 |
10.7 |
| GENEREX BIOTECHNOLOGY |
$1.83 |
63% |
83% |
$37 |
$12 |
$25 |
$2 |
23 |
$1.1 |
-$10.4 |
1.1 |
0.4 |
| GENETRONICS BIOMEDICAL LTD |
$1.04 |
87% |
593% |
$54 |
$2 |
$51 |
$0 |
26 |
$2.0 |
na |
na |
0.9 |
| KOS PHARMACEUTICALS |
$35.07 |
82% |
223% |
$753 |
$26 |
$727 |
$0 |
726 |
$1.0 |
na |
na |
3.4 |
| MACROCHEM CORP |
$0.94 |
57% |
-9% |
$27 |
$8 |
$19 |
$0 |
13 |
$1.5 |
-$4.7 |
1.6 |
0.4 |
| MEDICIS PHARMACEUTICAL |
$58.30 |
91% |
44% |
$1,583 |
$539 |
$1,045 |
$400 |
279 |
$3.7 |
na |
na |
3.6 |
| NASTECH PHARMACEUTICAL |
$9.01 |
75% |
11% |
$93 |
$17 |
$76 |
$4 |
63 |
$1.2 |
-$11.7 |
1.4 |
1.5 |
| NEKTAR THERAPEUTICS |
$12.73 |
85% |
183% |
$710 |
$252 |
$459 |
$399 |
680 |
$0.7 |
-$79.8 |
3.2 |
0.9 |
| NOVAVAX |
$7.30 |
94% |
78% |
$220 |
$14 |
$206 |
$41 |
121 |
$1.7 |
-$23.2 |
0.6 |
1.8 |
| NOVEN PHARMACEUTICALS |
$11.18 |
75% |
-6% |
$252 |
$65 |
$186 |
$0 |
274 |
$0.7 |
na |
na |
3.3 |
| SEPRACOR |
$28.20 |
86% |
458% |
$2,389 |
$482 |
$1,907 |
$983 |
818 |
$2.3 |
-$119.0 |
4.0 |
3.0 |
| Delivery Average |
|
74% |
147% |
$512 |
$101 |
$412 |
$104 |
|
$2.6 |
-$34.4 |
2.0 |
2.0 |
| Delivery Median |
|
75% |
75% |
$236 |
$37 |
$196 |
$0 |
|
$1.6 |
-$20.2 |
1.4 |
1.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ADVANCED MAGNETICS |
$9.64 |
70% |
94% |
$75 |
$15 |
$59 |
$0 |
23 |
$2.6 |
-$2.6 |
6.0 |
1.7 |
| BIOSITE |
$27.48 |
48% |
-3% |
$425 |
$72 |
$354 |
$7 |
513 |
$0.7 |
na |
na |
5.3 |
| CHOLESTECH CORP |
$7.92 |
61% |
-27% |
$110 |
$16 |
$94 |
$0 |
220 |
$0.4 |
-$14.8 |
1.1 |
1.3 |
| DIAGNOSTIC PRODUCTS CORP |
$35.65 |
75% |
-23% |
$1,025 |
$33 |
$992 |
$0 |
2100 |
$0.5 |
na |
na |
16.7 |
| DIGENE CORP |
$41.02 |
83% |
433% |
$761 |
$31 |
$730 |
$3 |
243 |
$3.0 |
-$2.5 |
12.5 |
6.6 |
| ENZO BIOCHEM |
$19.19 |
67% |
36% |
$547 |
$79 |
$467 |
$0 |
231 |
$2.0 |
na |
na |
3.4 |
| EPIX MEDICAL |
$15.72 |
76% |
242% |
$272 |
$21 |
$251 |
$0 |
93 |
$2.7 |
-$21.8 |
1.0 |
2.3 |
| EXACT SCIENCES |
$13.22 |
73% |
0% |
$253 |
$35 |
$218 |
$0 |
75 |
$2.9 |
-$31.5 |
1.1 |
2.2 |
| GEN-PROBE |
$51.70 |
75% |
542% |
$1,234 |
na |
na |
$0 |
186 |
na |
na |
na |
na |
| HYCOR BIOMEDICAL |
$5.05 |
78% |
189% |
$41 |
$5 |
$36 |
$0 |
148 |
$0.2 |
na |
na |
3.1 |
| IGEN INTERNATIONAL |
$57.60 |
96% |
89% |
$1,370 |
$42 |
$1,329 |
$45 |
370 |
$3.6 |
-$17.2 |
2.4 |
5.6 |
| IMMUCOR |
$28.71 |
91% |
88% |
$369 |
$5 |
$364 |
$20 |
481 |
$0.8 |
na |
na |
12.1 |
| LUMINEX |
$6.30 |
81% |
-9% |
$187 |
$39 |
$148 |
$0 |
117 |
$1.3 |
-$3.6 |
10.9 |
1.5 |
| MARTEK BIOSCIENCES CORP |
$51.79 |
88% |
209% |
$1,427 |
$103 |
$1,323 |
$0 |
198 |
$6.7 |
na |
na |
4.4 |
| MATRITECH |
$1.97 |
66% |
13% |
$63 |
$7 |
$56 |
$4 |
50 |
$1.1 |
-$7.8 |
0.9 |
0.8 |
| MERIDIAN BIOSCIENCE |
$9.87 |
86% |
80% |
$145 |
$3 |
$142 |
$23 |
350 |
$0.4 |
na |
na |
6.1 |
| ORASURE |
$9.50 |
87% |
139% |
$366 |
$15 |
$351 |
$3 |
187 |
$1.9 |
-$4.4 |
3.5 |
2.3 |
| QUIDEL CORP |
$6.41 |
84% |
56% |
$186 |
$13 |
$173 |
$10 |
330 |
$0.5 |
na |
na |
1.3 |
| SONUS PHARMACEUTICALS |
$5.24 |
81% |
212% |
$93 |
$14 |
$79 |
$0 |
37 |
$2.1 |
-$9.1 |
1.5 |
1.7 |
| TRINITY BIOTECH PLC |
$3.44 |
86% |
262% |
$136 |
$1 |
$135 |
$0 |
332 |
$0.4 |
na |
na |
6.3 |
| Diagnostic/imag. Average |
|
78% |
131% |
$454 |
$29 |
$384 |
$6 |
|
$1.8 |
-$11.5 |
4.1 |
4.5 |
| Diagnostic/imag. Median |
|
79% |
89% |
$263 |
$16 |
$218 |
$0 |
|
$1.3 |
-$8.5 |
2.0 |
3.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AASTROM BIOSCIENCES |
$1.53 |
84% |
467% |
$109 |
$5 |
$104 |
$0 |
44 |
$2.4 |
-$8.4 |
0.6 |
1.0 |
| AVIGEN |
$5.11 |
49% |
-37% |
$103 |
$105 |
-$2 |
$8 |
102 |
$0.0 |
-$23.9 |
4.4 |
0.4 |
| CELL GENESYS |
$12.56 |
82% |
6% |
$493 |
$161 |
$332 |
$60 |
336 |
$1.0 |
-$69.5 |
2.3 |
1.7 |
| CORAUTUS GENETICS |
$5.74 |
89% |
74% |
$57 |
$3 |
$55 |
$0 |
17 |
$3.2 |
-$85.8 |
0.0 |
0.9 |
| GENVEC |
$2.85 |
64% |
9% |
$65 |
$12 |
$54 |
$6 |
95 |
$0.6 |
-$20.6 |
0.6 |
0.6 |
| INTROGEN |
$9.40 |
84% |
375% |
$222 |
$19 |
$203 |
$7 |
50 |
$4.1 |
-$21.8 |
0.9 |
2.4 |
| SIRNA THERAPEUTICS |
$5.76 |
50% |
146% |
$164 |
$5 |
$159 |
$4 |
81 |
$2.0 |
-$19.7 |
0.2 |
0.8 |
| TARGETED GENETICS CORP |
$2.55 |
58% |
364% |
$149 |
$12 |
$137 |
$0 |
125 |
$1.1 |
-$3.3 |
3.7 |
0.7 |
| TRANSGENE SA |
$2.70 |
57% |
218% |
$81 |
na |
na |
$0 |
318 |
na |
na |
na |
na |
| TRANSKARYOTIC THERAPIES |
$11.00 |
32% |
-66% |
$386 |
$212 |
$174 |
$0 |
345 |
$0.5 |
-$103.8 |
2.0 |
0.6 |
| VALENTIS |
$3.01 |
25% |
-69% |
$17 |
$6 |
$11 |
$0 |
58 |
$0.2 |
-$12.1 |
0.5 |
0.1 |
| VICAL |
$5.97 |
77% |
75% |
$120 |
$102 |
$18 |
$0 |
165 |
$0.1 |
-$28.1 |
3.6 |
0.6 |
| Gene therapy Average |
|
63% |
130% |
$164 |
$58 |
$113 |
$7 |
|
$1.4 |
-$36.1 |
1.7 |
0.9 |
| Gene therapy Median |
|
61% |
75% |
$114 |
$12 |
$104 |
$0 |
|
$1.0 |
-$21.8 |
0.9 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AVANT IMMUNOTHERAPEUTICS |
$2.41 |
70% |
108% |
$156 |
$20 |
$137 |
$0 |
66 |
$2.1 |
-$13.4 |
1.5 |
0.7 |
| CUBIST PHARMACEUTICALS |
$10.10 |
68% |
128% |
$308 |
$114 |
$194 |
$208 |
204 |
$0.9 |
-$100.0 |
1.1 |
1.2 |
| EPIMMUNE |
$2.83 |
75% |
126% |
$35 |
$8 |
$27 |
$0 |
52 |
$0.5 |
-$7.2 |
1.0 |
0.2 |
| GENELABS TECHNOLOGIES |
$1.67 |
75% |
8% |
$106 |
$2 |
$104 |
$0 |
94 |
$1.1 |
-$16.8 |
0.1 |
0.6 |
| IMMUNE RESPONSE CORP |
$2.07 |
53% |
29% |
$67 |
$2 |
$65 |
$5 |
43 |
$1.5 |
-$20.8 |
0.1 |
0.3 |
| INTERMUNE |
$18.67 |
49% |
-41% |
$593 |
$277 |
$316 |
$150 |
250 |
$1.3 |
-$75.7 |
3.7 |
1.2 |
| INTRABIOTICS |
$11.40 |
55% |
-39% |
$37 |
$11 |
$26 |
$0 |
8 |
$3.2 |
-$7.6 |
1.5 |
0.2 |
| MEDIMMUNE |
$32.00 |
76% |
50% |
$7,995 |
$568 |
$7,427 |
$717 |
1505 |
$4.9 |
na |
na |
3.0 |
| NABI BIOPHARMACEUTICALS |
$8.22 |
86% |
52% |
$366 |
$47 |
$319 |
$0 |
722 |
$0.4 |
na |
na |
2.2 |
| SIGA TECHNOLOGIES |
$1.96 |
82% |
98% |
$34 |
$2 |
$32 |
$0 |
17 |
$1.9 |
-$121.5 |
0.0 |
1.0 |
| TRIMERIS |
$25.26 |
44% |
-43% |
$544 |
$140 |
$404 |
$0 |
129 |
$3.1 |
-$63.7 |
2.2 |
1.4 |
| VAXGEN |
$11.16 |
48% |
17% |
$229 |
$10 |
$218 |
$0 |
117 |
$1.9 |
-$26.6 |
0.4 |
1.4 |
| VICURON |
$16.83 |
94% |
106% |
$906 |
$145 |
$761 |
$0 |
28 |
$27.2 |
-$48.0 |
3.0 |
2.1 |
| VION PHARMACEUTICALS |
$1.63 |
54% |
352% |
$53 |
$8 |
$45 |
$0 |
34 |
$1.3 |
-$9.7 |
0.8 |
0.5 |
| VIROLOGIC |
$1.38 |
61% |
19% |
$46 |
$10 |
$36 |
$0 |
170 |
$0.2 |
-$9.9 |
1.0 |
0.4 |
| VIROPHARMA |
$2.75 |
58% |
175% |
$71 |
$145 |
-$73 |
$130 |
139 |
-$0.5 |
-$27.4 |
5.3 |
0.3 |
| XOMA LTD |
$7.36 |
69% |
26% |
$535 |
$33 |
$501 |
$71 |
229 |
$2.2 |
-$52.4 |
0.6 |
1.0 |
| Infection Average |
|
66% |
69% |
$711 |
$91 |
$620 |
$75 |
|
$3.1 |
-$40.0 |
1.5 |
1.0 |
| Infection Median |
|
68% |
50% |
$156 |
$20 |
$137 |
$0 |
|
$1.5 |
-$26.6 |
1.0 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AMYLIN PHARMACEUTICALS |
$27.15 |
88% |
71% |
$2,530 |
$455 |
$2,076 |
$175 |
350 |
$5.9 |
-$123.2 |
3.7 |
3.6 |
| BIOMARIN PHARMACEUTICAL |
$7.40 |
54% |
33% |
$472 |
$154 |
$318 |
$125 |
219 |
$1.5 |
-$78.7 |
2.0 |
1.2 |
| INSMED INC |
$2.79 |
75% |
580% |
$107 |
$0 |
$107 |
$0 |
23 |
$4.7 |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$3.34 |
84% |
123% |
$70 |
$22 |
$48 |
$0 |
24 |
$2.0 |
-$15.2 |
1.5 |
1.0 |
| NPS PHARMACEUTICALS |
$27.15 |
81% |
39% |
$999 |
$209 |
$790 |
$170 |
183 |
$4.3 |
-$112.4 |
1.9 |
2.0 |
| SAVIENT PHARMACEUTICALS |
$4.85 |
100% |
57% |
$288 |
$23 |
$265 |
$11 |
490 |
$0.5 |
na |
na |
1.3 |
| VIVUS |
$3.30 |
56% |
-27% |
$124 |
$23 |
$101 |
$0 |
119 |
$0.8 |
-$12.8 |
1.8 |
0.9 |
| ZONAGEN |
$1.75 |
89% |
65% |
$20 |
$24 |
-$4 |
$0 |
4 |
-$1.1 |
-$3.8 |
6.5 |
0.2 |
| Metabolic Average |
|
78% |
118% |
$576 |
$114 |
$463 |
$60 |
|
$2.3 |
-$57.7 |
2.9 |
1.5 |
| Metabolic Median |
|
82% |
61% |
$206 |
$24 |
$186 |
$6 |
|
$1.7 |
-$46.9 |
1.9 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| BIOPURE CORP |
$5.70 |
63% |
57% |
$253 |
$15 |
$238 |
$10 |
249 |
$1.0 |
-$46.6 |
0.3 |
0.6 |
| BIORELIANCE CORP |
$25.60 |
90% |
28% |
$213 |
$36 |
$178 |
$10 |
638 |
$0.3 |
na |
na |
3.8 |
| BIOTIME |
$1.90 |
64% |
64% |
$26 |
$1 |
$25 |
$2 |
12 |
$2.1 |
-$3.0 |
0.2 |
0.8 |
| CERUS |
$4.73 |
19% |
-71% |
$104 |
$96 |
$8 |
$51 |
158 |
$0.0 |
-$68.6 |
1.4 |
2.7 |
| COLLAGENEX PHARMACEUTICALS |
$10.50 |
62% |
63% |
$121 |
$10 |
$111 |
$0 |
148 |
$0.7 |
na |
na |
1.4 |
| COLUMBIA LABORATORIES |
$14.00 |
87% |
235% |
$550 |
$4 |
$547 |
$10 |
25 |
$21.9 |
-$18.8 |
0.2 |
4.3 |
| CURIS |
$4.29 |
77% |
270% |
$160 |
$37 |
$124 |
$7 |
64 |
$1.9 |
-$17.2 |
2.1 |
0.2 |
| CYANOTECH CORP |
$0.52 |
69% |
-7% |
$10 |
$1 |
$9 |
$4 |
58 |
$0.2 |
-$0.7 |
0.9 |
0.4 |
| CYTRX CORP |
$2.20 |
59% |
529% |
$63 |
$1 |
$62 |
$0 |
3 |
$20.6 |
-$3.7 |
0.4 |
0.8 |
| DISCOVERY LABORATORIES |
$7.45 |
88% |
319% |
$307 |
$14 |
$293 |
$0 |
65 |
$4.5 |
-$18.0 |
0.8 |
3.5 |
| INSITE VISION |
$0.55 |
44% |
-54% |
$14 |
$1 |
$13 |
$0 |
41 |
$0.3 |
-$9.1 |
0.1 |
0.1 |
| INSPIRE PHARMACEUTICALS |
$16.50 |
88% |
393% |
$524 |
$96 |
$428 |
$0 |
54 |
$7.9 |
na |
na |
2.6 |
| INTEGRA LIFESCIENCES |
$27.32 |
89% |
75% |
$730 |
$129 |
$601 |
$105 |
760 |
$0.8 |
na |
na |
2.5 |
| NORTHFIELD LABORATORIES |
$6.99 |
70% |
73% |
$113 |
$9 |
$103 |
$0 |
60 |
$1.7 |
-$11.6 |
0.8 |
1.0 |
| OSTEOTECH |
$9.45 |
58% |
0% |
$162 |
$15 |
$147 |
$15 |
338 |
$0.4 |
na |
na |
2.5 |
| PALATIN TECHNOLOGIES |
$4.21 |
80% |
96% |
$176 |
$26 |
$151 |
$0 |
46 |
$3.3 |
-$22.6 |
1.1 |
1.6 |
| PHARMACYCLICS |
$5.10 |
89% |
61% |
$83 |
$94 |
-$12 |
$0 |
133 |
-$0.1 |
-$28.8 |
3.3 |
0.3 |
| REPLIGEN CORP |
$5.46 |
64% |
136% |
$163 |
$18 |
$146 |
$0 |
39 |
$3.7 |
-$3.1 |
5.7 |
1.0 |
| SALIX PHARMACEUTICALS |
$18.95 |
94% |
146% |
$409 |
$40 |
$369 |
$0 |
135 |
$2.7 |
-$21.9 |
1.8 |
3.1 |
| TRIPOS |
$8.00 |
81% |
-3% |
$72 |
$10 |
$62 |
$4 |
337 |
$0.2 |
na |
na |
2.0 |
| Other Average |
|
72% |
120% |
$213 |
$33 |
$180 |
$11 |
|
$3.7 |
-$19.5 |
1.4 |
1.8 |
| Other Median |
|
73% |
68% |
$161 |
$15 |
$135 |
$1 |
|
$1.3 |
-$17.6 |
0.8 |
1.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AMGEN |
$65.15 |
90% |
55% |
$84,044 |
$4,757 |
$79,287 |
$3,056 |
10100 |
$7.9 |
na |
na |
4.3 |
| BIOGEN |
$39.04 |
77% |
33% |
$5,835 |
$812 |
$5,023 |
$37 |
2633 |
$1.9 |
na |
na |
7.0 |
| CHIRON CORP |
$51.61 |
90% |
46% |
$9,627 |
$843 |
$8,784 |
$564 |
4044 |
$2.2 |
na |
na |
3.9 |
| GENENTECH |
$80.39 |
91% |
151% |
$41,630 |
$1,085 |
$40,545 |
$0 |
5252 |
$7.7 |
na |
na |
6.3 |
| GENZYME CORP |
$46.00 |
88% |
122% |
$10,215 |
$515 |
$9,700 |
$600 |
5600 |
$1.7 |
na |
na |
3.7 |
| GILEAD SCIENCES |
$55.42 |
78% |
65% |
$11,159 |
$612 |
$10,547 |
$595 |
1250 |
$8.4 |
na |
na |
11.0 |
| IDEC PHARMACEUTICALS CORP |
$34.25 |
72% |
-19% |
$5,324 |
$860 |
$4,464 |
$871 |
995 |
$4.5 |
na |
na |
5.4 |
| Revenue-driven Average |
|
84% |
65% |
$23,976 |
$1,355 |
$22,621 |
$818 |
|
$4.9 |
na |
na |
5.9 |
| Revenue-driven Median |
|
88% |
55% |
$10,215 |
$843 |
$9,700 |
$595 |
|
$4.5 |
na |
na |
5.4 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| DIVERSA |
$7.65 |
63% |
-6% |
$328 |
$155 |
$173 |
$11 |
279 |
$0.6 |
-$83.9 |
1.8 |
1.0 |
| DYAX |
$5.33 |
71% |
147% |
$131 |
$31 |
$100 |
$18 |
244 |
$0.4 |
-$25.5 |
1.2 |
0.9 |
| ISIS PHARMACEUTICALS |
$6.41 |
58% |
-30% |
$356 |
$269 |
$87 |
$200 |
523 |
$0.2 |
-$97.3 |
2.8 |
0.6 |
| LIGAND PHARMACEUTICALS |
$12.06 |
73% |
95% |
$836 |
$34 |
$802 |
$159 |
402 |
$2.0 |
-$81.3 |
0.4 |
1.2 |
| NEUROGEN CORP |
$6.20 |
70% |
-14% |
$111 |
$71 |
$40 |
$14 |
163 |
$0.2 |
-$31.6 |
2.3 |
0.6 |
| ONYX PHARMACEUTICALS |
$20.00 |
82% |
359% |
$583 |
$38 |
$545 |
$0 |
89 |
$6.1 |
-$42.8 |
0.9 |
2.9 |
| REGENERON PHARMACEUTICALS |
$17.62 |
77% |
38% |
$918 |
$312 |
$606 |
$200 |
266 |
$2.3 |
-$120.4 |
2.6 |
1.5 |
| TULARIK |
$9.94 |
81% |
46% |
$587 |
$156 |
$430 |
$0 |
430 |
$1.0 |
-$96.8 |
1.6 |
1.4 |
| Screening Average |
|
72% |
79% |
$481 |
$133 |
$348 |
$75 |
|
$1.6 |
-$72.5 |
1.7 |
1.3 |
| Screening Median |
|
72% |
42% |
$469 |
$113 |
$302 |
$16 |
|
$0.8 |
-$82.6 |
1.7 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
09/26/03 Close |
% 52wk High |
% Change From 09/27/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| CARRINGTON LABORATORIES |
$4.08 |
63% |
304% |
$41 |
$2 |
$39 |
$2 |
252 |
$0.2 |
-$1.2 |
2.0 |
0.8 |
| CELLEGY PHARMACEUTICALS |
$2.90 |
48% |
40% |
$58 |
$12 |
$47 |
$0 |
23 |
$2.0 |
-$12.5 |
0.9 |
0.6 |
| CURATIVE HEALTH SERVICES |
$17.26 |
88% |
55% |
$219 |
$2 |
$217 |
$24 |
340 |
$0.6 |
na |
na |
2.1 |
| LIFECELL CORP |
$6.42 |
87% |
255% |
$137 |
$5 |
$132 |
$1 |
155 |
$0.8 |
na |
na |
1.7 |
| LIFECORE BIOMEDICAL |
$6.74 |
73% |
1% |
$87 |
$3 |
$84 |
$6 |
199 |
$0.4 |
na |
na |
1.8 |
| Wound Average |
|
72% |
131% |
$108 |
$5 |
$104 |
$7 |
|
$0.8 |
-$6.9 |
na |
1.4 |
| Wound Median |
|
73% |
55% |
$87 |
$3 |
$84 |
$2 |
|
$0.6 |
-$6.9 |
na |
1.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Grand Average |
|
74% |
113% |
$1,098 |
$139 |
$987 |
$72 |
|
$2.2 |
-$39.6 |
2.4 |
2.3 |
| Grand Median |
|
76% |
69% |
$220 |
$46 |
$167 |
$1 |
|
$1.3 |
-$24.5 |
1.6 |
1.3 |
originally published 10/09/2003 |